Literature DB >> 4267313

On the mechanism of the inhibitory action of the spirolactone SC 9376 (aldadiene) on the production of corticosteroids in rat adrenals in vitro.

H C Erbler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4267313     DOI： 10.1007/bf00501155

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  11 in total

1.  NEW VIEWPOINTS IN THE USE OF PROGESTERONE IN THE TREATMENT OF CARDIAC OEDEMAS ASSOCIATED WITH SECONDARY HYPERALDOSTERONISM.

Authors:  E GLAZ; K SUGAR
Journal:  Ther Hung       Date:  1964

2.  [A simple fluorometric method for the routine determination of corticosteroids in small quantities of plasma].

Authors:  F STAHL; I HERTLING; G KNAPPE
Journal:  Acta Biol Med Ger       Date:  1963

3.  Cytoplasmic bodies in the adrenal cortex of patients treated with spirolactone.

Authors:  D T JANIGAN
Journal:  Lancet       Date:  1963-04-20       Impact factor: 79.321

4.  Stimulation of aldosterone production in vitro and its inhibition by spironolactone.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

5.  Effect of spironolactone on the zona. Light and electron microscopy.

Authors:  E H Jenis; R W Hertzog
Journal:  Arch Pathol       Date:  1969-11

6.  [Aldadiene and other metabolites in the blood and urine after rectal appliacation of spironolactone and injection of aldaliene-potassium].

Authors:  H Wagner; F Weist; L Zicha
Journal:  Arzneimittelforschung       Date:  1967-04

7.  The influence of spironolactone on its own biotransformation.

Authors:  B Solymoss; S Tóth; S Varga; M Krajny
Journal:  Steroids       Date:  1970-09       Impact factor: 2.668

8.  Ultrastructural features of aldosterone production.

Authors:  E R Fisher; B Horvat
Journal:  Arch Pathol       Date:  1971-09

9.  Experimental production of so-called spironolactone bodies.

Authors:  E R Fisher; B Horvat
Journal:  Arch Pathol       Date:  1971-05

10.  A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.

Authors:  N GOCHMAN; C L GANTT
Journal:  J Pharmacol Exp Ther       Date:  1962-03       Impact factor: 4.030
View more
  13 in total

1.  Canrenoate disposition in dogs. Tissue distribution and elimination.

Authors:  J Kuhlmann; V Kötter; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-06       Impact factor: 3.000

2.  Selective inhibition of aldosterone synthesis by 11-hydroxylated spirolactone in rat adrenals.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

3.  A comparison of some extra-renal effects of spironolactone and canrenone.

Authors:  G J Huston; E A Al-Dujaili
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

4.  Inhibition of aldosterone production in diuretic-induced hyperaldosteronism by aldosterone antagonist canrenone in man.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

5.  The effect of saluretics and spironolactone on aldosterone production and electrolyte excretion in man.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  Salivary electrolytes in digitalis-treated patients with and without raised aldosterone excretion.

Authors:  H von Lilienfeld-Toal; R P Buckesfeld; H D Bolte; P G Lankisch; D Larbig
Journal:  Klin Wochenschr       Date:  1973-12-01

7.  Distal tubular segments of the rabbit kidney after adaptation to altered Na- and K-intake. I. Structural changes.

Authors:  B Kaissling; M Le Hir
Journal:  Cell Tissue Res       Date:  1982       Impact factor: 5.249

8.  Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; M Schöneshöfer; M L'age; W Oelkers
Journal:  Klin Wochenschr       Date:  1978-04-01

9.  Effect of aldosterone antagonist canrenone on plasma aldosterone concentration and plasma renin activity, and on the excretion of aldosterone and electrolytes by man.

Authors:  H C Erbler; H Wernze; M Hilfenhaus
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

10.  Non-interaction of spironolactone medication and cortisol metabolism in man.

Authors:  U Abshagen; S Spörl; M L'age
Journal:  Klin Wochenschr       Date:  1978-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.